Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
combined fixed dose combination
Gain Therapeutics
Tuberculosis
1 trial -
combined fixed dose combination
United Therapeutics Europe Ltd
Tuberculosis
1 trial -
conventional dose epinephrine
Hospital Authority, Hong Kong
Croup
1 trial -
half-dose ticagrelor
The First People's Hospital of Lianyungang
Acute Coronary Syndrome
1 trial -
inotuzumab ozogamicin-dose level 2
Pfizer
Leukemia
1 trial -
low-dose rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Atrial Fibrillation
1 trial -
low-dose tenecteplase intravenous thrombolysis
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke Patients
1 trial -
low-dose ticagrelor
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
low-dose ticagrelor
The First People's Hospital of Lianyungang
Platelet Reactivity
1 trial -
miglustat
Ultragenyx UK Limited
GM1 Gangliosidoses
1 trial -
split-virion, adjuvanted H1N1 vaccine of 7.5 ΞΌg per dose
Sinovac Research and Development Co.,
Influenza
1 trial -
A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.
The First People's Hospital of Lianyungang
Anal Fistula
1 trial -
CT colonoscopy(normal dose)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Polyps
1 trial -
Esketamine at low dose
The First People's Hospital of Lianyungang
Insomnia
1 trial -
GD007 Low-dose drug group
The First People's Hospital of Lianyungang
Moderate-Severe Intrauterine Adhesions
1 trial -
High Dose GGQL Decoction
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diabetes Mellitus, Type 2
1 trial -
High Dose Vitamin D
Atrium Therapeutics
Breast
1 trial -
High-dose vitamin D2 softgels
The First People's Hospital of Lianyungang
Chronic Kidney Disease 5D
1 trial -
Low dose Radiotherapy
United Therapeutics Europe Ltd
Covid19
1 trial -
Low dose midazolam
Hospital Authority, Hong Kong
Intubation
1 trial -
Multiple-dose of Ciprofloxacin prophylaxis
The First People's Hospital of Lianyungang
Kidney Stones
1 trial -
Phenytoin single dose (300 mg)
United Therapeutics Europe Ltd
Healthy
1 trial -
SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
The First People's Hospital of Lianyungang
SARS-CoV-2
1 trial -
Single dose of 2L PEG
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Health Behavior
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources